Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update
Portfolio Pulse from
Rigel Pharmaceuticals reported Q3 2024 financial results with total revenue of $55.3 million, including sales from TAVALISSE, REZLIDHIA, and GAVRETO. They entered an agreement with Kissei for REZLIDHIA in Asia, receiving a $10 million upfront payment. Initial data on R289 will be presented at the ASH Annual Meeting.
November 07, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rigel Pharmaceuticals reported Q3 2024 revenue of $55.3 million, with significant contributions from TAVALISSE, REZLIDHIA, and GAVRETO. A new partnership with Kissei for REZLIDHIA in Asia resulted in a $10 million upfront payment.
The financial results show strong revenue performance, particularly from key products. The partnership with Kissei for REZLIDHIA in Asia is a strategic move that provides immediate financial benefit and potential future growth, likely boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100